The 23rd Jiangsu Digestive Disease Academic Conference, sponsored by the Jiangsu Medical Association and the Digestive Disease Branch of the Jiangsu Medical Association, and co organized by the Affiliated Hospital of Jiangsu University, will be held from July 7-9, 2023 at the Sheraton Hotel in Kanghua Hui Li, Zhenjiang. This conference will invite many well-known experts in the province to interpret and discuss the latest developments in the field of gastroenterology, promoting the construction and development of the discipline of gastroenterology.

On July 9th, the IBD sub forum sponsored by Nanjing Daoqun Group, the "Novomedetomidine" Satellite Conference, will be held in the banquet hall 3 on the 3rd floor of the Sheraton Hotel in Zhenjiang. The "Novomedetomidine" Satellite Conference will be chaired by Xu Min, Deputy Secretary and Vice Dean of the Party Committee and Dean of the Digestive Disease Research Institute of Jiangsu University Affiliated Hospital. Zhang Hongjie, Chief Physician of the First Affiliated Hospital of Nanjing Medical University and member of the IBD Group of the Digestive Disease Branch of the Chinese Medical Association, will give a lecture on the application of mesalazine in the management of chronic ulcerative colitis.

Nanjing Daoqun Group was founded in 2008, with the mission of "helping medical care and protecting health", making full use of the digital economy to empower the group, relying on the advantages of the Internet, and integrating medical industry chain resources to create an Internet medical smart health platform, to provide digital medical services for the industry, including drug sales research and development, medical device sales research and development, Internet plus medicine, and so on.

The company is based in East China, with business channels covering the whole country. With a high-quality and diversified product portfolio, a professional academic promotion network, an efficient operational management system, and an international development perspective, it has achieved sustained high-speed growth.

     Hainan Herui Pharmaceutical Co., Ltd. was established in 2009 and is a high-tech enterprise specializing in the development, production, and sales of sustained-release and diversified generic drugs. As of now, 26 product codes have been approved for listing, and 17 products are currently under research. The core of enterprise operation is driven by research and development, based on efficiency and cost, to provide patients with high-quality and accessible drugs.